Nexvet Biopharma on Monday set terms of its planned initial public offering, saying in a filing with the U.S. Securities and Exchange Commission it expects 4 million ordinary shares to be priced between $13 to $16 a share. Nexvet has applied for its shares to be traded under the "NVET" ticker on the Nasdaq Global Market. Nexvet is developing therapeutic monoclonal antibodies aimed at treating pain in dogs and cats, and inflammatory disease in dogs.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below